# MAGED1

## Overview
MAGED1, or melanoma-associated antigen D1, is a gene that encodes the MAGE family member D1 protein, which is involved in a variety of cellular processes, including apoptosis, cell cycle regulation, and differentiation. The protein is categorized as an adaptor molecule, playing a crucial role in ubiquitin-dependent degradation pathways and acting as a co-factor for transcription. It is particularly significant in neural development and the regulation of circadian rhythms (Wang2018Inhibition). MAGED1 interacts with several key proteins, such as the neurotrophin receptor p75NTR and members of the IAP family, to mediate apoptotic signaling (Bertrand2004Comparative). In the nervous system, it is essential for normal oxytocin production, influencing social behaviors and food intake (Dombret2012Loss). Additionally, MAGED1's interactions with proteins like CREB and PPARγ highlight its involvement in synaptic function, learning, memory, and adipocyte differentiation (Yang2014Maged1; Wang2018Inhibition). The gene's expression and function have clinical implications in conditions such as Parkinson's disease, colorectal cancer, and mood disorders, making it a subject of interest in medical research (Zeng2012Prognostic; Mouri2012MAGED1; Wang2023The).

## Function
MAGED1 (MAGE family member D1) is involved in various cellular processes, including apoptosis, cell cycle regulation, and differentiation. It acts as an adaptor for ubiquitin-dependent degradation pathways and a co-factor for transcription, playing a significant role in neural development and circadian rhythm regulation (Wang2018Inhibition). MAGED1 interacts with the neurotrophin receptor p75 NTR to promote apoptosis through the activation of caspases and the JNK signaling pathway. It also interacts with members of the IAP family, which are inhibitors of apoptosis, and binds to the axon guidance receptor UNC5H1, facilitating apoptotic signaling (Bertrand2004Comparative).

In the nervous system, MAGED1 is highly expressed and is crucial for the production of normal levels of oxytocin in the hypothalamus, which influences social and emotional behaviors, as well as food intake (Dombret2012Loss). It is also involved in the regulation of transcriptional activity of homeodomain proteins such as Msx2 and Dlx5, suggesting a role in neural differentiation and maintenance (Bertrand2004Comparative). MAGED1's interaction with CREB is essential for co-activating CREB-dependent transcription, which is important for synapse formation and transmission, impacting learning and memory (Yang2014Maged1).

## Clinical Significance
Alterations in the expression of the MAGED1 gene have been implicated in several diseases and conditions. In Parkinson's disease (PD), MAGED1 is expressed in dopaminergic neurons and its deficiency in mice has been shown to attenuate disease progression. This is achieved through reduced apoptosis and enhanced autophagy, suggesting that MAGED1 plays a role in the balance between these processes in PD. The gene's interaction with the neurotrophin receptor p75NTR and its influence on p53 transcriptional activity are also noted, indicating its involvement in cell death pathways (Wang2023The).

In colorectal cancer, MAGED1 expression is significantly down-regulated in tumor tissues compared to non-tumorous tissues. This down-regulation is associated with advanced disease stages and poorer differentiation, making MAGED1 a potential prognostic biomarker for colorectal carcinoma (Zeng2012Prognostic).

MAGED1 is also involved in mood disorders, particularly depression. MAGE-D1 knockout mice exhibit depression-like behaviors, which are linked to altered serotonin transporter (SERT) metabolism. The gene's role in SERT ubiquitylation affects serotonin levels, suggesting its significance in serotonergic signaling and depression pathogenesis (Mouri2012MAGED1).

## Interactions
MAGED1 interacts with several proteins, playing a role in various cellular processes. It functions as an adaptor molecule in the ubiquitin-dependent degradation pathway, interacting with the serotonin transporter (SERT) to regulate its ubiquitylation and stability. This interaction is mediated through the necdin homology domain (NHD) of MAGED1, which is crucial for binding with SERT (Mouri2012MAGED1). In the central nervous system, MAGED1's interaction with SERT is significant for modulating serotonergic function and is implicated in depression-like behaviors (Mouri2012MAGED1).

MAGED1 also interacts with the cAMP response element-binding protein (CREB), which is essential for learning and memory. This interaction involves a unique 25-hexapeptide repeat region in MAGED1, necessary for CREB-dependent transcription (Yang2014Maged1). In the context of adipogenesis, MAGED1 binds to peroxisome proliferator-activated receptor-γ (PPARγ), inhibiting its stability and transcriptional activity, which affects adipocyte differentiation and insulin sensitivity (Wang2018Inhibition).

In cancer biology, MAGED1 forms complexes with E3 RING ubiquitin ligases, such as PRAJA-1 and TRIM28, influencing protein degradation pathways (Zhang2020The; Wang2018Inhibition). These interactions highlight MAGED1's role in diverse biological processes through its ability to bind and modulate the activity of various proteins.


## References


[1. (Dombret2012Loss) Carlos Dombret, Tuan Nguyen, Olivier Schakman, Jacques L. Michaud, Hélène Hardin-Pouzet, Mathieu J.M. Bertrand, and Olivier De Backer. Loss of maged1 results in obesity, deficits of social interactions, impaired sexual behavior and severe alteration of mature oxytocin production in the hypothalamus. Human Molecular Genetics, 21(21):4703–4717, August 2012. URL: http://dx.doi.org/10.1093/hmg/dds310, doi:10.1093/hmg/dds310. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/dds310)

[2. (Yang2014Maged1) JianJun Yang, BeiBei Lai, AiLi Xu, Yu Liu, XiaoMin Li, YongNa Zhao, WeiFeng Li, MuHuo Ji, Gang Hu, Xiang Gao, and Jun Gao. Maged1 co-interacting with creb through a hexapeptide repeat domain regulates learning and memory in mice. Molecular Neurobiology, 51(1):8–18, April 2014. URL: http://dx.doi.org/10.1007/s12035-014-8677-x, doi:10.1007/s12035-014-8677-x. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12035-014-8677-x)

[3. (Wang2023The) Jie Wang, Sheng-Ye Xu, Zhi-Yuan Ye, Zhou-Na Sun, Jia-Qi Zhang, Cui Qi, Rui Liu, Xiang Gao, Chuan He, Wei-Yan You, and Jun Gao. The deficiency of maged1 attenuates parkinson’s disease progression in mice. Molecular Brain, February 2023. URL: http://dx.doi.org/10.1186/s13041-023-01011-3, doi:10.1186/s13041-023-01011-3. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13041-023-01011-3)

[4. (Zhang2020The) Bin Zhang, Dan Li, Xin Jin, and Kun Zhang. The cdk4/6 inhibitor pd0332991 stabilizes fbp1 by repressing maged1 expression in pancreatic ductal adenocarcinoma. The International Journal of Biochemistry &amp; Cell Biology, 128:105859, November 2020. URL: http://dx.doi.org/10.1016/j.biocel.2020.105859, doi:10.1016/j.biocel.2020.105859. This article has 5 citations.](https://doi.org/10.1016/j.biocel.2020.105859)

[5. (Mouri2012MAGED1) Akihiro Mouri, Aya Sasaki, Ken Watanabe, Chiharu Sogawa, Shigeo Kitayama, Takayoshi Mamiya, Yoshiaki Miyamoto, Kiyofumi Yamada, Yukihiro Noda, and Toshitaka Nabeshima. Mage-d1 regulates expression of depression-like behavior through serotonin transporter ubiquitylation. The Journal of Neuroscience, 32(13):4562–4580, March 2012. URL: http://dx.doi.org/10.1523/jneurosci.6458-11.2012, doi:10.1523/jneurosci.6458-11.2012. This article has 69 citations.](https://doi.org/10.1523/jneurosci.6458-11.2012)

[6. (Zeng2012Prognostic) Zhao-lei Zeng, Wen-jing Wu, Jing Yang, Zhen-jie Tang, Dong-liang Chen, Miao-zhen Qiu, Hui-yan Luo, Zhi-qiang Wang, Ying Jin, De-shen Wang, and Rui-hua Xu. Prognostic relevance of melanoma antigen d1 expression in colorectal carcinoma. Journal of Translational Medicine, August 2012. URL: http://dx.doi.org/10.1186/1479-5876-10-181, doi:10.1186/1479-5876-10-181. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1479-5876-10-181)

[7. (Bertrand2004Comparative) Mathieu Bertrand, Ivo Huijbers, Patrick Chomez, and Olivier De Backer. Comparative expression analysis of the maged genes during embryogenesis and brain development. Developmental Dynamics, 230(2):325–334, April 2004. URL: http://dx.doi.org/10.1002/dvdy.20026, doi:10.1002/dvdy.20026. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/dvdy.20026)

[8. (Wang2018Inhibition) Qinghua Wang, Jing Tang, Shujun Jiang, Zan Huang, Anying Song, Siyuan Hou, Xiang Gao, and Hai-Bin Ruan. Inhibition of pparγ, adipogenesis and insulin sensitivity by maged1. Journal of Endocrinology, 239(2):167–180, November 2018. URL: http://dx.doi.org/10.1530/joe-18-0349, doi:10.1530/joe-18-0349. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1530/joe-18-0349)